[Effect of palivizumab prophylaxis in reducing the complications associated with the respiratory syncytial virus in infants and young children]

Breton M-C, Rossignol M, Fansi A, Jehanno C
Record ID 32017000010
Authors' recomendations: The currently available data indicate that palivizumab is effective in reducing the risk of RSV hospitalization in preterm infants with or without CLD, non-preterm infants with CLD, infants with acyanotic congenital heart disease, infants in remote communities, and children with Down syndrome with risk factors. Few scientific data are available for the other outcome measures evaluated, and the results of the different studies are sometimes discordant. None of the data identified support the efficacy of palivizumab in children with cystic fibrosis. The efficacy of palivizumab in certain populations, such as preterm infants with CLD, infants in remote communities, children with Down syndrome and children with cystic fibrosis, is very sparsely documented, and the studies contain methodological limitations and various uncertainties. Furthermore, no studies were found concerning the efficacy of palivizumab prophylaxis compared to the administration of placebo or to no prophylaxis in immunocompromised infants or young children, those with a metabolic disease, a severe neuromuscular disorder affecting respiratory function or an anomaly of the upper respiratory tract affecting respiratory function, or those of a multiple birth who are healthy but whose twin qualifies for palivizumab.
Project Status: Completed
Year Published: 2016
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Humans
  • Child
  • Infant
  • Palivizumab
  • Respiratory Syncytial Virus Infections
  • Respiratory Syncytial Virus, Human
Organisation Name: Institut national d'excellence en sante et en services sociaux
Contact Address: L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369
Contact Name: demande@inesss.qc.ca
Contact Email: demande@inesss.qc.ca
Copyright: ©Gouvernement du Québec/Institut national d'excellence en santé et en services sociaux
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.